PharmaMar: Switzerland first in Europe to authorise Zepzelca for lung cancer
PharmaMar on Wednesday announced the temporary marketing approval of Zepzelca, a lung cancer drug for adults, in Switzerland, the first European country to give the green light to lurbinectedin.
In a note sent to the Spanish Securities and Exchange Commission (CNMV), the company welcomes the authorisation of this treatment, which will be marketed directly by PharmaMar’s team, and which brings “hope” to these patients.
Zepzelca is intended for the treatment of metastatic small-cell lung cancer in adults with disease progression during or after platinum-based chemotherapy without central nervous system metastasis.
The temporary authorisation is granted under certain conditions defined by law in order to make medicines available to patients as soon as possible for the treatment of life-threatening diseases with limited therapeutic options.
In any case, it is subject to confirmation of the Phase III trial (LAGOON) in second-line small-cell lung cancer, which started in December 2021.
